Monograph

The Ministry of Health’s Drug Advisory Committee has not recommended recombinant zoster vaccine (RZV) for listing on the MOH Subsidised Vaccine List for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. The decision was based on the unfavourable cost-effectiveness of RZV and the absence of a price-volume agreement in the company’s proposal.